Redeye initiates coverage of Cyxone
2021-04-26 08:40:00
Redeye initiates coverage of Cyxone, a Swedish biotech company developing disease-modifying drugs for Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS), as well as a treatment for Covid-19. An experienced management team, a de-risked lead candidate and undemanding valuation underpin our interest in the case.
Read more and download the Research Report.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/